Kyleena

Levonorgestrel, the active ingredient in Kyleena, is a synthetic progestin presented as a 19.5 mg intrauterine system (IUS) for intrauterine placement. It provides continuous, hormone‑based contraception by releasing levonorgestrel locally within the uterus, thereby preventing pregnancy in women of reproductive age for up to five years.

GNH USA supplies Kyleena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and offering regulatory‑supported distribution across multiple markets.

Kyleena, a levonorgestrel‑releasing intrauterine system, is indicated for hormonal contraception.

- Contraception (prevention of pregnancy): provides highly effective, reversible birth control for up to five years. - Long‑acting reversible contraception (LARC): eliminates the need for daily or monthly dosing. - User convenience: reduces reliance on user‑dependent methods and improves adherence.

Kyleena may cause a range of adverse reactions. The majority are mild and resolve with continued use.

Common Side Effects: - Irregular vaginal bleeding or spotting. - Amenorrhea (absence of periods). - Pelvic or cramping pain after insertion. - Breast tenderness or mild hormonal changes.

Serious or Rare Side Effects: - Uterine perforation during insertion. - IUS expulsion or displacement. - Pelvic inflammatory infection. - Ectopic pregnancy if contraception fails. - Severe allergic reaction (e.g., rash, swelling).

Before prescribing Kyleena, clinicians should consider several safety measures.

- Pregnancy screening: confirm the patient is not pregnant prior to insertion. - Uterine assessment: evaluate for fibroids, congenital anomalies, or scarring. - Infection control: treat any active pelvic infection before placement. - Medication review: identify drugs that may reduce contraceptive efficacy. - Bleeding counseling: inform patients about possible changes in menstrual patterns. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from Kyleena can be affected by other medicines.

Major Interactions (Avoid): - CYP3A4 inducers (e.g., rifampicin, phenytoin): may markedly lower levonorgestrel levels. - Anticonvulsants (e.g., carbamazepine, phenobarbital): can reduce contraceptive effectiveness.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole, itraconazole): may increase hormone exposure. - Certain antibiotics (e.g., tetracycline, metronidazole): limited evidence, monitor for breakthrough bleeding. - Herbal supplements (e.g., St. John’s wort): potential to alter hormone metabolism.